Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

Stopped The Sponsor elected to discontinue the study prematurely due to business reasons

Conditions

• Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women

Interventions

• DRUG: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
• DRUG: Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

Sponsor

AMAG Pharmaceuticals, Inc.